Trials, Tribunals, and Opportunities for Lung Cancer KRASG12C Brain Metastases.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

The activity of KRAS inhibitors against brain metastases is relatively unexplored. The recent work on preclinical models and preliminary data from the ongoing KRYSTAL-1 phase Ib clinical trial support the potential of adagrasib (MRTX849) to penetrate the central nervous system and provide control of KRASG12C brain metastases. See related article by Sabari et al., p. 3318.

Keyphrases

brain metastases
small cell lung cancer
clinical trial
electronic health record
big data
randomized controlled trial
stem cells
study protocol
cell therapy
human health
mesenchymal stem cells
wild type
phase iii